A new study presented at an annual meeting of the American Society of Clinical Oncology has shown hopes of cancer drug Avastin, used to treat breast cancer, delaying the progression of ovarian cancer.
During the research 484 women whose ovarian cancer had recurred after an initial drug treatment received two standard drugs used to fight the disease, while half also received Avastin.
On average, the women who used Avastin lived 12.4 months before their cancer worsened, while the others reached 8.4 months before their cancer progressed.
After two years on the test drug, more women were still alive, but not statistically significant. The findings prompted Dr. Caral Aghajanian, the lead investigator of the study, to determine:
"It really is not appropriate statistically to say we really know anything about overall survival here."
While the FDA is moving to revoke the approval of Avastin to treat breast cancer because the drug has not prolonged lives in clinical trials, the drug's manufacturer has filed for approval in Europe to market the drug as a treatment for ovarian cancer.